Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-Current Debt (2022 - 2025)

UroGen Pharma's Non-Current Debt history spans 4 years, with the latest figure at $122.2 million for Q4 2025.

  • For Q4 2025, Non-Current Debt changed 0.39% year-over-year to $122.2 million; the TTM value through Dec 2025 reached $122.2 million, changed 0.39%, while the annual FY2025 figure was $122.2 million, 0.39% changed from the prior year.
  • Non-Current Debt reached $122.2 million in Q4 2025 per URGN's latest filing, roughly flat from $122.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $122.5 million in Q2 2025 to a low of $70.8 million in Q1 2022.
  • Average Non-Current Debt over 4 years is $102.0 million, with a median of $98.4 million recorded in 2023.
  • Peak YoY movement for Non-Current Debt: soared 38.34% in 2023, then dropped 0.49% in 2024.
  • A 4-year view of Non-Current Debt shows it stood at $97.5 million in 2022, then rose by 1.04% to $98.6 million in 2023, then rose by 23.52% to $121.7 million in 2024, then increased by 0.39% to $122.2 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Non-Current Debt are $122.2 million (Q4 2025), $122.1 million (Q3 2025), and $122.5 million (Q2 2025).